How much does peptide therapy cost?

Published prices for prescribed peptide programs start around $99 to $250 a month, before consultations and labs. The number that actually matters is the annual one, because the withdrawal trials show what happens when treatment stops.

Published September 14, 2026

This page reports what published studies found. It is not medical advice, no provider-patient relationship is created by reading it, and nothing here is a recommendation to use any compound. Talk with a licensed clinician about your own situation. Read the full disclaimer.

Four ways to buy, four price structures

"Peptide therapy" is sold through four distinct channels, and their prices are not comparable because they are not the same purchase.

Telehealth programs

An online intake, a video or asynchronous clinician visit, a prescription, and medication shipped from a compounding pharmacy. This is the most transparent lane, because most programs publish something. Among the ten programs profiled on this site in September 2026, published monthly figures included sermorelin from about $99 to $200, NAD+ from about $120 to $144, compounded semaglutide from about $139 to $159, and compounded tirzepatide from about $219 to $239. One program published a peptide range of $99 to $299 a month sold as ten-week courses; another published nothing at all until after intake. Each figure, and the date it was read, sits on that program's own page under online programs.

In-person clinics

Clinics and medical spas usually price per visit or per protocol rather than per month, and they rarely publish figures at all, which is why our directorylists clinics without prices. Expect an initial consultation fee, lab work, and a medication charge as separate lines. In-person administration costs more than shipping a vial to someone's door, and includes something different.

Branded prescriptions through insurance

For approved products such as semaglutide and tirzepatide, what someone pays depends on their plan, their diagnosis, prior authorization and manufacturer savings programs, so two people with the same prescription can pay wildly different amounts. Published list prices bear little relationship to what an insured patient actually pays, in either direction.

Research-chemical vendors

The lowest sticker prices in the market, for material labelled not for human use, sold without a prescriber, a pharmacy, or any verification of what is in the vial. Our vendor pages describe that market and the enforcement around it. Treating its prices as a discount on a prescription misunderstands what is being compared.

What drives the price

• The compound. Compounded tirzepatide consistently prices above compounded semaglutide, which prices above sermorelin, across the programs we checked.
• Dose. Many programs price by strength, so a dose escalation is a price escalation.
• What is bundled. Some prices include the clinician visit, shipping and follow-up; others add a membership fee and charge labs separately.
• Labs. Programs that require baseline bloodwork add a real cost, and one that is sometimes billed to insurance even when the medication is not.
• Commitment length. Introductory rates that assume a three-month plan are common, and the renewal price is the one that matters.
• State. Program availability and pricing vary by state, and some programs do not operate in every state at all.

The cost question the trials answer

Two randomized withdrawal trials bear directly on how long someone is budgeting for. In STEP 4, participants reached a semaglutide maintenance dose during a 20-week run-in, losing a mean of 10.6 percent, and were then randomized to continue or switch to placebo for 48 weeks; continuing produced further loss and stopping produced regain. In SURMOUNT-4, 670 adults who had lost a mean of 20.9 percent during a 36-week tirzepatide lead-in were randomized for 52 more weeks: mean weight change from week 36 to week 88 was -5.5 percent on continued tirzepatide and +14.0 percent on placebo, and 89.5 percent of those continuing kept at least 80 percent of their lead-in loss against 16.6 percent on placebo.

Whatever the monthly figure is, the trial evidence describes an ongoing treatment rather than a course with an end date. That is the single most useful thing to know before signing up.

Pricing red flags

• A headline price that only applies to the first month, with the renewal rate hard to find.
• No named prescriber, or no way to reach one before paying.
• Prices that appear only after an intake questionnaire and a card on file.
• Long prepaid packages with no refund terms in writing.
• Claims of results, or comparisons to trial numbers, attached to a compound with no trials.
• Any offer to supply a prescription medication without a prescriber involved.

How to compare two programs honestly

Put both on the same footing: same compound, same dose, twelve months, including every consultation and lab charge, and check whether each is a compounded preparation or an approved product. Our comparison table lists what each program publishes, with the date it was checked, and each program page records its pricing notes verbatim. Where a program publishes nothing, the page says so rather than guessing.

Frequently asked questions